Oral mineralocorticoid-receptor antagonists: Real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy

Translational Vision Science and Technology

Volumn 5, Issue 2, 2016, Pages

  Daruich, Alejandra ^a   Matet, Alexandre ^a   Dirani, Ali ^a   Gallice, Mathilde ^a   Nicholson, Luke ^b   Sivaprasad, Sobha ^b   Behar Cohen, Francine ^a,c,d,e  

^a JULES GONIN EYE HOSPITAL   (Switzerland)

^b Moorfields NIHR Ophthalmology Biomedical Research Centre   (United Kingdom)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Central serous chorioretinopathy; Choroid; Drug related side effects and adverse reactions; Epleronone; Mineralocorticoidreceptor antagonist; Retinal pigment epithelium; Spironolactone; Treatment

Indexed keywords

EPLERENONE; SPIRONOLACTONE;

ADULT; ARTICLE; AUTOFLUORESCENCE IMAGING; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CENTRAL SEROUS RETINOPATHY; CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FLUORESCENCE ANGIOGRAPHY; GYNECOMASTIA; HUMAN; HYPERKALEMIA; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; SUBRETINAL FLUID; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL SYSTEM PARAMETERS;

EID: 84992521522     PISSN: None     EISSN: 21642591     Source Type: Journal    
DOI: 10.1167/tvst.5.2.2     Document Type: Article

References (26)

1. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010; 149:361-363.
2. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol. 1992;2:103- 114.
3. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina. 2008; 28:1008-1012.
4. Ooto S, Hangai M, Sakamoto A, et al. Highresolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology. 2010;117: 1800-1809.
5. Piccolino FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol. 2005;139:87-99.
6. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103-126.
7. Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clin Ophthalmol. 2013; 7:1867-1875.
8. Chan W-M, Lai TYY, Lai RYK, Liu DTL, Lam DSC. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756-1765.
9. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95:457-466.
10. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122: 2672-2679.
11. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82-115.
12. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33:2096-2102.
13. Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefes Arch Clin Exp Ophthalmol. 2014;252:1985-1991.
14. Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol. 2015;8:310-314.
15. Bousquet E, Beydoun T, Rothschild P-R, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35:2505-2515.
16. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070-2079. discussion 2079-2080.
17. Swissmedic. Available at: http://www. swissmedicinfo.ch. Accessed 12 July 2015.
18. Electronic Medicines Compendium. Available at http://www.medicines.org.uk. Accessed 12 July 2015.
19. Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups swissmedicinfo.ch. . J Am Coll Cardiol. 2013;62:1585-1593.
20. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16: 203-213.
21. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469-1473.
22. Yang L, Jonas JB, Wei W. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2013;54:4659-4665.
23. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J. 2010;24:3405- 3415.
24. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012; 350:310-317.
25. Kang NH, Kim YT. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. Eye Lond Engl. 2013;27:387-391.
26. Kim DY, Joe SG, Yang HS, Lee JY, Kim J-G, Yoon YH. Subfoveal choroidal thickness changes in treated idiopathic central serous chorioretinopathy and their association with recurrence. Retina. 2015;35:1867-1874.